Clinical Trials Directory

Trials / Conditions / HER2 + Breast Cancer

HER2 + Breast Cancer

27 registered clinical trials studyying HER2 + Breast Cancer — 17 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingPragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer
NCT07428018
Mario Negri Institute for Pharmacological ResearchPhase 2
RecruitingA Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Bre
NCT07294508
Shanghai Henlius BiotechPhase 2 / Phase 3
RecruitingNeoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
NCT07393425
Shanghai Jiao Tong University School of MedicinePhase 2
Not Yet RecruitingA Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzu
NCT07294534
Shanghai Henlius BiotechPhase 2 / Phase 3
RecruitingPhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
NCT07222215
Kristina A. FanucciPhase 2
RecruitingEvaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Brea
NCT07211178
Tempus AI—
RecruitingA First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metast
NCT07081555
AffibodyPhase 1
Not Yet RecruitingSHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response
NCT07129187
Chuan WangPhase 2
Not Yet RecruitingEfficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
NCT07136974
Henan Cancer HospitalPhase 2
Active Not RecruitingA Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
NCT06878248
Calibr, a division of Scripps ResearchPhase 1
Active Not RecruitingHER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
NCT06844669
Washington University School of MedicinePhase 2
RecruitingHER2-positive Breast Cancer Registry
NCT06603597
Priyanka Sharma—
Not Yet RecruitingPyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER
NCT06537674
Jiangsu Famous Medical Technology Co., Ltd.—
RecruitingBreast Cancer Evolution During Neoadjuvant Systemic Therapy
NCT06681064
Royal Marsden NHS Foundation Trust—
Active Not RecruitingPersonalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable
NCT06663787
Nagoya City University—
RecruitingA Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871
Iambic Therapeutics, IncPhase 1
RecruitingRADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
NCT07030569
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano—
RecruitingRC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II S
NCT07065435
The First Affiliated Hospital with Nanjing Medical UniversityPhase 2
CompletedNeoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed
NCT05931042
Rawalpindi Medical College—
RecruitingA Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Trea
NCT05534438
Memorial Sloan Kettering Cancer CenterPhase 2
TerminatedBN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
NCT04296942
National Cancer Institute (NCI)Phase 1
UnknownPrecise Therapy for Refractory HER2 Positive Advanced Breast Cancer
NCT05429684
First Affiliated Hospital Xi'an Jiaotong UniversityPhase 3
RecruitingThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750
PMV Pharmaceuticals, IncPhase 1 / Phase 2
Active Not RecruitingA Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
NCT03632941
Herbert LyerlyPhase 2
CompletedA Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cance
NCT01598077
Novartis PharmaceuticalsPhase 1
TerminatedPhase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
NCT01132664
Novartis PharmaceuticalsPhase 1 / Phase 2